A long-term extension study of maridebart cafraglutide in adults with obesity or overweight (MARITIME-1-EXTENSION)
Not Yet Recruiting Phase 3 NCT07684235
Study Description
A follow-up study to find out how safe and effective the weight loss medication maridebart cafraglutide is when taken over a longer period of time in people who are overweight or living with obesity
Study Details
- Registry ID:
- NCT07684235
- Conditions:
- Obesity, Overweight
- Phase:
- Phase 3
- Target Enrollment:
- 3,200 participants
- Start Date:
- Age Range:
- 18–99 years
- Healthy Volunteers:
- No
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.